Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan could sharpen radiation for Fast-Growing brain cancers

NCT ID NCT05608395

First seen Oct 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times

Summary

This study tested whether a PET/CT scan using 11C-methionine, a radioactive amino acid, could improve radiotherapy planning for people with glioblastoma (a fast-growing brain cancer) whose tumors worsen soon after surgery. Thirty-three patients received the scan before starting chemo-radiation, and their outcomes were compared to a historical group. The goal was to see if this extra imaging leads to better survival by targeting the tumor more accurately.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Masaryk Memorial Cancer Institute

    Brno, Czech Republic, 65653, Czechia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

11C-methionine (a radioactive amino acid used in PET/CT scans)

What this could lead to

If successful, this imaging technique could help doctors create more precise radiotherapy plans for aggressive brain tumors, potentially improving survival.

What could go wrong

This is a small, early-phase study with only 33 participants. The benefit over standard MRI-based planning is not yet proven, and the radioactive tracer may not significantly change outcomes.

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.